Document is current
Any future updates will be listed below
-
Authors
Jaberi-Douraki, Majid
Xu, Xuan
Dima, Danai
Ailawadhi, Sikander https://orcid.org/0000-0002-8377-8111
Anwer, Faiz https://orcid.org/0000-0001-6914-7439
Mazzoni, Sandra
Valent, Jason
Habib, Muhammad Hamza
Riviere, Jim E.
Raza, Shahzad https://orcid.org/0000-0002-2739-2265
-
Funding
Funding for this research was provided by:
BioNexus KC for this project (BioNexus KC 20-7 Nexus of Animal and Human Health Research Grant
- License Information
-
More Information
Article History
Received: 15 September 2024
Revised: 2 December 2024
Accepted: 10 December 2024
First Online: 20 December 2024
Competing interests
: Majid Jaberi-Douraki accepted funding from BioNexus KC for this project (BioNexus KC 20-7 Nexus of Animal and Human Health Research Grant). Sikander Ailawadhi has a consulting relationship with GlaxoSmithKline (GSK), Sanofi, Bristol Myers Squibb Foundation (BMS), Takeda, Beigene, Pharmacyclics, Amgen, Janssen, Regeneron, Cellectar, Pfizer and research funding (outside of this study) from GSK, BMS, Pharmacyclics, Amgen, Janssen, Cellectar, Abbvie, Ascentage. Faiz Anwer has consulting relationships with BMS, Caribou Biosciences and received research funding (outside of this study) from Celgene, Acetylon Pharmaceuticals, Millennium, Astellas Pharma, AbbVie, Janssen, Bristol Myers Squibb, and Caribou Biosciences. Dr. Sandra Mazzoni has a consulting agreement with Janssen/J&J Consulting. Shahzad Raza received an honorarium as an advisory board for Pfizer, Prothena Biosciences, and KiTE pharma and received research funding (outside of this study) from Nexcella Inc, Poseida Therapeutics and Janssen. The other authors declare no conflicts of interest.
